Search results
Tesaro Inc. is a pharmaceutical company based in Waltham, Massachusetts. They focus on drug development for cancer.
Dec 3, 2018 · TESARO is a commercial-stage biopharmaceutical company, with a major marketed product, Zejula (niraparib), an oral poly ADP ribose polymerase (PARP) inhibitor currently approved for use in ovarian cancer.
Jan 22, 2019 · GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that it has successfully completed the acquisition of TESARO, Inc. an oncology-focused company based in Waltham, Massachusetts, for an aggregate cash consideration of approximately $5.1 billion (£4.0 billion).
On 3 December 2018 we announced our agreement to acquire TESARO, an oncology-focused company based in the US for approximately $5.1bn. The proposed transaction will significantly strengthen our pharmaceutical business, accelerating the build of our pipeline and commercial capability in oncology.
Dec 17, 2018 · Tesaro was, after all, standing at just $46 the last trading day before GSK's $5.1 billion announcement. What happened in between? Back-and-forth talks and rejections from multiple companies, the...
Find the latest Tesaro, Inc. (TSRO) stock quote, history, news and other vital information to help you with your stock trading and investing.
TESARO is an oncology-focused business within GlaxoSmithKline (GSK) with a clear mission that drives all of our actions. We are dedicated to improving the oncology experience and have a...
Dec 3, 2018 · GlaxoSmithKline will acquire Tesaro, a Massachusetts-based oncology firm, for $5.1 billion, the two companies announced Monday. The takeover will give the British drugmaker control of Zejula, Tesaro’s PARP inhibitor and leading therapeutic asset.
Jan 23, 2019 · GlaxoSmithKline ( GSK) has completed its acquisition of US-based biopharmaceutical company Tesaro for an aggregate cash consideration of $5.1bn. An agreement for the acquisition was signed in December last year. The deal boosts GSK’s pharmaceutical business by supporting its oncology pipeline.
Dec 3, 2018 · GlaxoSmithKline (GSK) has agreed to acquire Tesaro for approximately $5.1 billion, in a deal the buyer said would “significantly” accelerate the development of its pipeline and commercial...
